US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

CNS/Neurology: market research reports

RSS Feeds

CNS/Neurology market research reports and industry analysis

3  4  5  6    8    10  11  12  
Ergot Alkaloids (Migraine) - Forecast and Market Analysis to 2023
3/31/2014 | published by: GlobalData
... the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of ...  |  read more...
USD 3,495
Beta Blockers (Migraine) - Forecast and Market Analysis to 2023
3/31/2014 | published by: GlobalData
... the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of ...  |  read more...
USD 3,495
Anti-Epileptics (Migraine) - Forecast and Market Analysis to 2023
3/31/2014 | published by: GlobalData
... next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies ...  |  read more...
USD 3,495
Lasmiditan (Migraine) - Forecast and Market Analysis to 2023
3/31/2014 | published by: GlobalData
... next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies ...  |  read more...
USD 3,495
MK-1602 (Migraine) - Forecast and Market Analysis to 2023
3/31/2014 | published by: GlobalData
... next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies ...  |  read more...
USD 3,495
Triptans (Migraine) - Forecast and Market Analysis to 2023
3/31/2014 | published by: GlobalData
... next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies ...  |  read more...
USD 3,495
PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2023
3/31/2014 | published by: GlobalData
... during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes ...  |  read more...
USD 9,995
Narcolepsy - Pipeline Review, H1 2014
3/31/2014 | published by: Global Markets Direct
... Narcolepsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It ...  |  read more...
USD 2,000
PharmaPoint: Migraine - US Drug Forecast and Market Analysis to 2023
3/31/2014 | published by: GlobalData
... during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes ...  |  read more...
USD 4,995
PharmaPoint: Migraine - 5EU Drug Forecast and Market Analysis to 2023
3/31/2014 | published by: GlobalData
... during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes ...  |  read more...
USD 6,995
PharmaPoint: Migraine - Japan Drug Forecast and Market Analysis to 2023
3/31/2014 | published by: GlobalData
... during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes ...  |  read more...
USD 4,995
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2014
3/31/2014 | published by: Global Markets Direct
... therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of ...  |  read more...
USD 2,000
Sumavel DosePro (Migraine) - Forecast and Market Analysis to 2023
3/31/2014 | published by: GlobalData
... the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of ...  |  read more...
USD 3,495
Antidepressants (Migraine) - Forecast and Market Analysis to 2023
3/31/2014 | published by: GlobalData
... next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies ...  |  read more...
USD 3,495
Calcium Channel Antagonists (Migraine) - Forecast and Market Analysis to 2023
3/31/2014 | published by: GlobalData
... during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes ...  |  read more...
USD 3,495
Botox (Migraine) - Forecast and Market Analysis to 2023
3/31/2014 | published by: GlobalData
... next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies ...  |  read more...
USD 3,495
Zecuity (Migraine) - Forecast and Market Analysis to 2023
3/31/2014 | published by: GlobalData
... next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies ...  |  read more...
USD 3,495
Levadex (Migraine) - Forecast and Market Analysis to 2023
3/31/2014 | published by: GlobalData
... next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies ...  |  read more...
USD 3,495
RHB-103 (Migraine) - Forecast and Market Analysis to 2023
3/31/2014 | published by: GlobalData
... next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies ...  |  read more...
USD 3,495
AVP-825 (Migraine) - Forecast and Market Analysis to 2023
3/31/2014 | published by: GlobalData
... next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies ...  |  read more...
USD 3,495
SUD-001 (Migraine) - Forecast and Market Analysis to 2023
3/31/2014 | published by: GlobalData
... next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies ...  |  read more...
USD 3,495
Neuroblastoma Global Clinical Trials Review, H1, 2014
3/27/2014 | published by: GlobalData
... relating to the clinical trials on Neuroblastoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage ...  |  read more...
USD 2,500
High-Grade Glioma Global Clinical Trials Review, H1, 2014
3/19/2014 | published by: GlobalData
... information and data relating to the clinical trials on High-Grade Glioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook ...  |  read more...
USD 2,500
OpportunityAnalyzer: Autism Spectrum Disorder - Opportunity Analysis and Forecasts to 2018
3/12/2014 | published by: GlobalData
... is off-label use of a multitude of other drugs which target different core and non-core symptoms of ASD. Since this disorder can first become apparent in very young children there is a need for medications ...  |  read more...
USD 5,995
Medical Robots Market by Type (Surgical Robot, Rehabilitation Robotics, Telemedicine, Assistive Robots, Orthotics, Prosthetics, Radio Surgery, Exoskeleton) & Application (Orthopedic, Neurology, Laparoscopy)- Global Forecasts to 2018
3/11/2014 | published by: MarketsandMarkets
... which comprises surgical robots, rehabilitation robots, non-invasive radiosurgery robots, hospital and pharmacy robots, and other robotic systems, has witnessed various technological advancements. These advancements have led to a growth in the number of application areas ...  |  read more...
USD 4,650
3  4  5  6    8    10  11  12